GeneDx Stock (NASDAQ:WGS)
Previous Close
$54.32
52W Range
$32.21 - $170.87
50D Avg
$55.46
200D Avg
$101.15
Market Cap
$1.81B
Avg Vol (3M)
$1.25M
Beta
1.97
Div Yield
-
WGS Company Profile
GeneDx Holdings Corp. functions as a health intelligence firm singularly focused on the individual patient. It aims to revolutionize healthcare delivery by deploying advanced artificial intelligence and machine learning capabilities. These sophisticated algorithms are applied to vast, longitudinal clinical and genomic datasets to construct comprehensive, dynamic models of human health, ultimately defining personalized, optimal pathways for each person's well-being. Through its exclusive Centrellis health intelligence platform, the company gains profound insights into both disease states and overall wellness, enabling it to furnish evidence-based solutions for the most critical medical challenges. Eric Schadt established the corporation in October 2015, and its principal offices are located in Stamford, Connecticut.
WGS Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
| Product/Service | Dec 25 | Dec 24 | Dec 22 |
|---|---|---|---|
| Diagnostic Test, Self Pay | $1.36M | $2.34M | - |
| Diagnostic Test, Third Party Insurance | $345.24M | $234.70M | - |
| Product and Service, Other | $10.87M | $3.29M | $7.36M |
| Diagnostic Test | $416.67M | $302.16M | $227.33M |
| Diagnostic Test, Institutional Customers | $70.07M | $65.11M | - |
Fiscal year ends in Dec 25 | Currency in USD